Research programme: vitamin A signal amplifiers - OPKO HealthAlternative Names: Vitamin A signal amplifiers research programme - Cytochroma
Latest Information Update: 08 Mar 2013
At a glance
- Originator Cytochroma
- Mechanism of Action Retinoic acid metabolism modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Mar 2013 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 Mar 2013 OPKO Health acquires Cytochroma
- 22 Jul 2004 Preclinical trials in Cancer in USA (unspecified route)